CLINICAL_TRIALS
trial_result
· 2020-12-19
Clinical Trial Update: An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus [Phase 2]
Summary
Phase 2 extension study of GDC-0853 in moderate to severe active systemic lupus erythematosus has been terminated; results posted in 2020.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Genentech, Inc. | Conditions: Lupus Erythematosus, Systemic | Phase 2 | Status: TERMINATED | Results posted: 2020-12-19